3ʳᵈ Edition of the Cancer R&D World Conference 2027

Speakers - CRDWC 2027

Andras Szasz, Cancer R&D World Conference, Miami, Florida, USA

Andras Szasz

Andras Szasz

  • Designation: Hungarian University of Agriculture and Life Sciences, XAX Consulting LLC
  • Country: Hungary/USA
  • Title: Electro-Oncology: Extending Survival While Preserving Quality of Life

Abstract

Modern oncology has transformed outcomes for many patients, yet two problems remain unsolved. First, the toxicity of standard therapies limits dosing and erodes quality of life, and it excludes the most fragile patients from treatment altogether. Second, cytotoxic selection pressure favors resistant clones, so each line of therapy tends to leave a more aggressive disease behind. This keynote argues that a group of physical, field-based treatments now forms a coherent clinical discipline, electro-oncology, that addresses both problems.

Electro-oncology uses precisely configured electric and electromagnetic fields to act selectively on malignant tissue. Its selectivity comes from the biophysical differences of tumors: altered dielectric and conductive properties, membrane characteristics, metabolism, and disordered tissue structure. The discipline rests on three pillars that cover the whole course of disease.

Tumor Treating Fields (TTFields) deliver low-intensity alternating fields at 100–300 kHz that disrupt the mitotic spindle. Randomized evidence supports their first-line use in glioblastoma and pleural mesothelioma, in patients with good performance status. Their benefit at relapse is markedly weaker.

Modulated electro-hyperthermia (mEHT) applies an amplitude-modulated 13.56 MHz carrier through impedance-matched capacitive coupling. Unlike conventional hyperthermia, it concentrates energy in the tumor rather than heating the volume homogeneously. It induces apoptosis and immunogenic cell death (calreticulin exposure, HMGB1, HSP70, and ATP release), acting as an in situ tumor vaccine; abscopal responses have also been reported. A Phase III randomized trial in locally advanced cervical cancer showed improved local disease control and survival when mEHT was added to chemoradiation. Phase II data cover liver, rectal, lung, pancreatic, ovarian, and breast cancers. Because mEHT causes no myelosuppression and no systemic organ toxicity, it serves advanced, heavily pretreated, and fragile patients (ECOG 2–4), where TTFields and most standard options end.

The third pillar is quantum mechanical vector-potential effects, a research frontier. By Maxwell's equations, the modulated mEHT signal generates a broadband, time-varying vector potential in tissue. Preclinical studies show that modulated treatment outperforms unmodulated treatment at the same carrier frequency. We propose, as a testable hypothesis, that part of this difference reflects Aharonov–Bohm-type phase coupling to membrane and water systems.

The three pillars share a clinical profile: selectivity, minimal systemic toxicity, immune engagement, and no cytotoxic selection pressure toward resistant clones. Together they form a continuum from first-line treatment through refractory disease. The discipline has two co-primary aims: longer overall survival and preserved or improved quality of life. Electro-oncology does not compete with immuno-oncology; it can prime it, including in patients who have progressed on checkpoint inhibitors.

The talk will set out the evidence and its limits, and the trials needed to consolidate the field: confirmatory Phase III studies of mEHT, sham-controlled modulation studies, and mEHT combined with checkpoint inhibitor re-challenge